Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK.
Ogura Y, Jaffe GJ, Cheung CMG, Kokame GT, Iida T, Takahashi K, Lee WK, Chang AA, Monés J, D'Souza D, Weissgerber G, Gedif K, Koh A. Ogura Y, et al. Among authors: weissgerber g. Br J Ophthalmol. 2022 Jul;106(7):994-999. doi: 10.1136/bjophthalmol-2021-319090. Epub 2021 Jul 22. Br J Ophthalmol. 2022. PMID: 34301613 Free PMC article. Clinical Trial.
Challenges, facilitators and barriers to screening study participants in early disease stages-experience from the MACUSTAR study.
Terheyden JH, Behning C, Lüning A, Wintergerst L, Basile PG, Tavares D, Melício BA, Leal S, Weissgerber G, Luhmann UFO, Crabb DP, Tufail A, Hoyng C, Berger M, Schmid M, Silva R, Martinho CV, Cunha-Vaz J, Holz FG, Finger RP; MACUSTAR consortium. Terheyden JH, et al. Among authors: weissgerber g. BMC Med Res Methodol. 2021 Mar 17;21(1):54. doi: 10.1186/s12874-021-01243-8. BMC Med Res Methodol. 2021. PMID: 33731014 Free PMC article.
Use of Composite End Points in Early and Intermediate Age-Related Macular Degeneration Clinical Trials: State-of-the-Art and Future Directions.
Terheyden JH, Schmitz-Valckenberg S, Crabb DP, Dunbar H, Luhmann UFO, Behning C, Schmid M, Silva R, Cunha-Vaz J, Tufail A, Weissgerber G, Leal S, Holz FG, Finger RP; on behalf of the MACUSTAR Consortium. Terheyden JH, et al. Among authors: weissgerber g. Ophthalmologica. 2021;244(5):387-395. doi: 10.1159/000513591. Epub 2020 Dec 7. Ophthalmologica. 2021. PMID: 33285549 Free article. Review.
Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study.
Holz FG, Dugel PU, Weissgerber G, Hamilton R, Silva R, Bandello F, Larsen M, Weichselberger A, Wenzel A, Schmidt A, Escher D, Sararols L, Souied E. Holz FG, et al. Among authors: weissgerber g. Ophthalmology. 2016 May;123(5):1080-9. doi: 10.1016/j.ophtha.2015.12.030. Epub 2016 Feb 20. Ophthalmology. 2016. PMID: 26906165 Free article. Clinical Trial.
A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration.
Poor SH, Weissgerber G, Adams CM, Bhatt H, Browning DJ, Chastain J, Ciulla TA, Ferriere M, Gedif K, Glazer LC, Joondeph BC, Normand G, Sheth V, Watters C, Grosskreutz CL. Poor SH, et al. Among authors: weissgerber g. Am J Ophthalmol. 2022 Jul;239:180-189. doi: 10.1016/j.ajo.2022.02.019. Epub 2022 Mar 2. Am J Ophthalmol. 2022. PMID: 35247334 Free article. Clinical Trial.
20 results